Cerus Company Profile (NASDAQ:CERS)

About Cerus (NASDAQ:CERS)

Cerus logoCerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:CERS
  • CUSIP: 15708510
  • Web: www.cerus.com
Capitalization:
  • Market Cap: $234.9 million
  • Outstanding Shares: 103,938,000
Average Prices:
  • 50 Day Moving Avg: $3.73
  • 200 Day Moving Avg: $4.36
  • 52 Week Range: $2.19 - $7.64
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.35
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $36.56 million
  • Price / Sales: 6.43
  • Book Value: $0.40 per share
  • Price / Book: 5.65
Profitability:
  • EBIDTA: ($62,240,000.00)
  • Net Margins: -174.76%
  • Return on Equity: -76.76%
  • Return on Assets: -49.53%
Debt:
  • Debt-to-Equity Ratio: 0.20%
  • Current Ratio: 4.72%
  • Quick Ratio: 4.19%
Misc:
  • Average Volume: 1.14 million shs.
  • Beta: 2.06
  • Short Ratio: 12.85
 

Frequently Asked Questions for Cerus (NASDAQ:CERS)

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.02. The company had revenue of $7.01 million for the quarter, compared to analyst estimates of $8.98 million. Cerus had a negative return on equity of 76.76% and a negative net margin of 174.76%. View Cerus' Earnings History.

Where is Cerus' stock going? Where will Cerus' stock price be in 2017?

5 equities research analysts have issued 12 month price objectives for Cerus' shares. Their predictions range from $7.00 to $10.00. On average, they expect Cerus' share price to reach $8.40 in the next year. View Analyst Ratings for Cerus.

What are analysts saying about Cerus stock?

Here are some recent quotes from research analysts about Cerus stock:

  • 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (3/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $9 PT following mixed 4Q16 results and strong 2017 guidance. The company reports that 55 U.S. hospitals have begun receiving INTERCEPT platelets, with a pipeline of ~10 more expected in 1Q17 and additional hospitals expected in 2Q17. Driving that adoption is the key to 2017, in our view, and the company is sharply focused on driving hospital adoption through expanded medical science liaisons and hospital implementation teams. That said, some hospitals are already ordering as many units as are available and others are not yet in use due to capacity constraints, which we expect to be alleviated as more of the 36 installed systems come online. We continue to believe 2017 may be a breakout year as U.S. INTERCEPT utilization drives kit sales and the company progresses with both its U.S. and European red blood cell programs." (3/8/2017)

Who are some of Cerus' key competitors?

Who owns Cerus stock?

Cerus' stock is owned by a number of of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (7.53%), ELK CREEK PARTNERS, LLC (5.17%), Vanguard Group Inc. (4.55%), Elk Creek Partners LLC (4.19%), Peregrine Capital Management LLC (3.47%) and Wells Fargo & Company MN (3.11%). Company insiders that own Cerus stock include Carol Moore, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

Who sold Cerus stock? Who is selling Cerus stock?

Cerus' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Credit Suisse AG, Alliancebernstein L.P., Teachers Advisors LLC, Parametric Portfolio Associates LLC, Stoneridge Investment Partners LLC, ProShare Advisors LLC and Goldman Sachs Group Inc.. Company insiders that have sold Cerus stock in the last year include Carol Moore, Kevin Dennis Green, Richard J Benjamin and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Who bought Cerus stock? Who is buying Cerus stock?

Cerus' stock was bought by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, First Midwest Bank Trust Division, Point72 Asset Management L.P., Vanguard Group Inc., Peregrine Capital Management LLC, Formula Growth Ltd., Wells Fargo & Company MN and Bank of America Corp DE. View Insider Buying and Selling for Cerus.

How do I buy Cerus stock?

Shares of Cerus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cerus stock cost?

One share of Cerus stock can currently be purchased for approximately $2.26.

Analyst Ratings

Consensus Ratings for Cerus (NASDAQ:CERS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.40 (271.68% upside)

Analysts' Ratings History for Cerus (NASDAQ:CERS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017Cantor FitzgeraldSet Price TargetBuy$7.00HighView Rating Details
4/17/2017Cowen and CompanyLower Price TargetOutperform$9.50 -> $7.00LowView Rating Details
3/10/2017BTIG ResearchReiterated RatingBuy$8.00N/AView Rating Details
3/8/2017FBR & CoSet Price TargetBuy$10.00LowView Rating Details
8/6/2016Robert W. BairdSet Price TargetBuy$9.00 -> $10.00N/AView Rating Details
2/6/2016StephensReiterated RatingBuyN/AView Rating Details
12/17/2015WedbushDowngradeOutperform -> Neutral$6.50N/AView Rating Details
6/30/2015MLV & Co.Reiterated RatingBuy$10.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Cerus (NASDAQ:CERS)
Earnings by Quarter for Cerus (NASDAQ:CERS)
Earnings History by Quarter for Cerus (NASDAQ:CERS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.17)($0.18)$8.98 million$7.01 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.16)($0.13)$11.29 million$10.10 millionViewListenView Earnings Details
11/3/2016Q316($0.17)($0.14)$10.34 million$10.20 millionViewN/AView Earnings Details
8/4/2016Q216($0.17)($0.18)$8.88 million$9.25 millionViewN/AView Earnings Details
5/3/2016Q1($0.16)($0.17)$8.29 million$7.60 millionViewN/AView Earnings Details
3/8/2016Q415($0.16)($0.15)$9.72 million$9.70 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.17)$10.00 million$8.04 millionViewN/AView Earnings Details
8/6/2015Q215($0.15)($0.17)$8.71 million$8.83 millionViewN/AView Earnings Details
5/5/2015Q214($0.16)($0.21)$7.70 million$7.70 millionViewN/AView Earnings Details
2/26/2015Q114($0.15)($0.25)$10.36 million$9.70 millionViewN/AView Earnings Details
11/4/2014Q413($0.13)($0.15)$9.83 million$10.36 millionViewN/AView Earnings Details
7/31/2014Q313($0.13)($0.16)$8.17 million$8.60 millionViewN/AView Earnings Details
5/1/2014Q313($0.09)($0.04)$9.65 million$7.86 millionViewN/AView Earnings Details
2/25/2014Q213($0.09)($0.10)$11.77 million$9.23 millionViewN/AView Earnings Details
10/29/2013($0.09)($0.29)$10.34 million$10.54 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cerus (NASDAQ:CERS)
2017 EPS Consensus Estimate: ($0.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.15)($0.15)($0.15)
Q2 20171($0.14)($0.14)($0.14)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cerus (NASDAQ:CERS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cerus (NASDAQ:CERS)
Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 68.91%
Insider Trades by Quarter for Cerus (NASDAQ:CERS)
Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)
Insider Trades by Quarter for Cerus (NASDAQ:CERS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/15/2017Kevin Dennis GreenCFOSell2,343$4.21$9,864.03View SEC Filing  
3/15/2017William Mariner GreenmanInsiderSell8,786$4.21$36,989.06View SEC Filing  
3/14/2017Carol MooreSVPSell2,377$4.15$9,864.55View SEC Filing  
3/14/2017Richard J BenjaminInsiderSell1,189$4.15$4,934.35View SEC Filing  
8/22/2016Kevin Dennis GreenCFOSell17,150$6.80$116,620.00View SEC Filing  
8/19/2015Laurence M CorashInsiderBuy25,900$4.99$129,241.00View SEC Filing  
8/18/2015Laurence M CorashInsiderBuy84,600$4.77$403,542.00View SEC Filing  
11/10/2014William Mariner GreenmanCEOBuy21,800$3.93$85,674.00View SEC Filing  
11/19/2012William Mariner GreenmanCEOBuy3,200$3.02$9,664.00View SEC Filing  
11/16/2012Laurence M CorashInsiderBuy2,000$2.85$5,700.00View SEC Filing  
11/16/2012William Mariner GreenmanCEOBuy13,800$2.85$39,330.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cerus (NASDAQ:CERS)
Latest Headlines for Cerus (NASDAQ:CERS)
Source:
DateHeadline
thestreet.com logoBiotech Movers: Cerus, Alexion, NantKwest - TheStreet.com
www.thestreet.com - May 25 at 12:19 AM
americanbankingnews.com logoCerus Co. (CERS) PT Set at $7.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 23 at 10:37 PM
finance.yahoo.com logoHere's Why Cerus Corporation Stock Is Tanking Today
finance.yahoo.com - May 23 at 4:14 PM
finance.yahoo.com logoCerus Provides U.S. Business Update
finance.yahoo.com - May 23 at 12:52 PM
finance.yahoo.com logoCerus stock plunges 16% after news of temporary impact to US blood centers, revenue warning
finance.yahoo.com - May 23 at 12:52 PM
finance.yahoo.com logoETFs with exposure to Cerus Corp. : May 22, 2017
finance.yahoo.com - May 22 at 4:08 PM
finance.yahoo.com logoClass Of 1997: 2 Decades After Their IPOs, Where Are These Companies Now?
finance.yahoo.com - May 16 at 12:43 PM
streetinsider.com logoCerus (CERS) Says First Patient Transfused in Phase III RedeS Study Evaluating INTERCEPT Red Blood Cell System
www.streetinsider.com - May 15 at 12:40 PM
finance.yahoo.com logoFirst Patient Transfused in Cerus’ Phase III RedeS Study Evaluating Safety and Efficacy of the INTERCEPT Red Blood Cell System
finance.yahoo.com - May 15 at 12:40 PM
americanbankingnews.com logoCerus Co. (CERS) Expected to Announce Quarterly Sales of $10.86 Million
www.americanbankingnews.com - May 14 at 10:50 AM
americanbankingnews.com logoCerus Co. (CERS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 12 at 10:36 AM
americanbankingnews.com logo-$0.16 EPS Expected for Cerus Co. (CERS) This Quarter
www.americanbankingnews.com - May 12 at 8:14 AM
finance.yahoo.com logoETFs with exposure to Cerus Corp. : May 11, 2017
finance.yahoo.com - May 11 at 4:50 PM
finance.yahoo.com logoCerus Corp. :CERS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 4:24 PM
seekingalpha.com logoBARDA extends support of development of Cerus' INTERCEPT RBCs
seekingalpha.com - May 9 at 4:14 PM
finance.yahoo.com logoCerus Announces Exercise of Additional BARDA Contract Options Totaling $46.6 million to Support INTERCEPT Red Blood Cell System Development
finance.yahoo.com - May 9 at 4:14 PM
americanbankingnews.com logoCantor Fitzgerald Reiterates "$9.00" Price Target for Cerus Co. (CERS)
www.americanbankingnews.com - May 7 at 12:28 AM
americanbankingnews.com logoCerus Co. (CERS) Releases Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 4 at 4:42 PM
finance.yahoo.com logoCerus Corp. breached its 50 day moving average in a Bearish Manner : CERS-US : May 4, 2017
finance.yahoo.com - May 4 at 4:21 PM
finance.yahoo.com logoHere's Why Cerus Corporation Dropped as Much as 33.2% This Morning
finance.yahoo.com - May 4 at 4:21 PM
finance.yahoo.com logoEdited Transcript of CERS earnings conference call or presentation 3-May-17 8:15pm GMT
finance.yahoo.com - May 4 at 4:21 PM
fool.com logoHere's Why Cerus Corporation Dropped as Much as 33.2% This Morning
www.fool.com - May 4 at 1:09 PM
seekingalpha.com logoCerus' (CERS) CEO Obi Greenman on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 9:16 PM
finance.yahoo.com logoCerus reports 1Q loss
finance.yahoo.com - May 3 at 9:16 PM
finance.yahoo.com logoCerus Corporation Reports First Quarter 2017 Results
finance.yahoo.com - May 3 at 4:15 PM
americanbankingnews.com logoSomewhat Critical Media Coverage Extremely Likely to Impact Cerus (CERS) Share Price
www.americanbankingnews.com - May 3 at 12:37 PM
finance.yahoo.com logoInvestor Network: Cerus Corporation to Host Earnings Call
finance.yahoo.com - May 3 at 8:49 AM
americanbankingnews.com logoCerus (CERS) Given Daily Media Sentiment Score of 0.22
www.americanbankingnews.com - April 29 at 5:47 PM
americanbankingnews.com logoCerus Co. (CERS) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:23 AM
americanbankingnews.com logoCerus Co. (CERS) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:17 AM
americanbankingnews.com logoCerus (CERS) Given Daily News Impact Score of -0.12
www.americanbankingnews.com - April 25 at 1:08 PM
finance.yahoo.com logoCerus Corp. – Value Analysis (NASDAQ:CERS) : April 24, 2017
finance.yahoo.com - April 24 at 4:09 PM
americanbankingnews.com logo$8.98 Million in Sales Expected for Cerus Co. (CERS) This Quarter
www.americanbankingnews.com - April 23 at 9:30 AM
finance.yahoo.com logoCerus Corp. breached its 50 day moving average in a Bullish Manner : CERS-US : April 21, 2017
finance.yahoo.com - April 21 at 4:21 PM
americanbankingnews.com logoZacks: Brokerages Expect Cerus Co. (CERS) Will Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - April 21 at 11:23 AM
finance.yahoo.com logoCerus to Release First Quarter 2017 Results on May 3, 2017
finance.yahoo.com - April 19 at 12:56 PM
americanbankingnews.com logoCerus (CERS) Getting Somewhat Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 18 at 2:14 PM
americanbankingnews.com logoCerus Co. (CERS) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 17 at 2:17 PM
americanbankingnews.com logoCowen and Company Reiterates "Outperform" Rating for Cerus Co. (CERS)
www.americanbankingnews.com - April 17 at 1:14 PM
americanbankingnews.com logoPositive Press Coverage Somewhat Likely to Impact Cerus (CERS) Share Price
www.americanbankingnews.com - April 14 at 7:57 PM
nasdaq.com logoRussia suspends 2015 agreement on operations in Syria - Presented by: The Aol. On Network
www.nasdaq.com - April 8 at 10:41 AM
nasdaq.com logoStocks dip on jobs data, Syria - Presented by: The Aol. On Network
www.nasdaq.com - April 7 at 4:15 PM
finance.yahoo.com logoCerus Corp. breached its 50 day moving average in a Bearish Manner : CERS-US : April 5, 2017
finance.yahoo.com - April 7 at 8:55 AM
finance.yahoo.com logoETFs with exposure to Cerus Corp. : April 5, 2017
finance.yahoo.com - April 7 at 8:55 AM
finance.yahoo.com logoCerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - April 7 at 8:55 AM
americanbankingnews.com logoCantor Fitzgerald Equities Analysts Reduce Earnings Estimates for Cerus Co. (CERS)
www.americanbankingnews.com - March 23 at 9:32 AM
americanbankingnews.com logoCerus (CERS) – Research Analysts’ Weekly Ratings Updates
www.americanbankingnews.com - March 17 at 9:07 PM
americanbankingnews.com logoWilliam Mariner Greenman Sells 8,786 Shares of Cerus Co. (CERS) Stock
www.americanbankingnews.com - March 16 at 8:45 AM
finance.yahoo.com logoCERUS CORP Financials
finance.yahoo.com - March 14 at 4:07 PM
americanbankingnews.com logoCerus Co. (CERS) Upgraded by Zacks Investment Research to “Hold”
www.americanbankingnews.com - March 14 at 8:31 AM

Social

Chart

Cerus (CERS) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff